Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haipeng Xu

Showing results (91-100 of 95) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 95 results.
Lancet (London, England)|May 31, 2026
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in ChinaShun Lu, Baogang Liu, Yongzhong Luo, et al.
Lancet (London, England)|October 22, 2025
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trialZhiwei Chen, Fang Yang, Zhou Jiang, et al.
JAMA Surgery|July 15, 2026
Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non-Small Cell Lung Cancer: Post Hoc Analysis of the Neotorch Randomized Clinical TrialWentao Fang, Yiyang Wang, Wenxiang Wang, et al.
Thoracic Cancer|November 14, 2023
Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancerDingzhi Huang, Gen Lin, Qian Chu, et al.
Thoracic Cancer|January 14, 2024
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancerGen Lin, Zhijie Wang, Qian Chu, et al.
Pageof 10

Showing results (91-100 of 95) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 95 results.
Lancet (London, England)|May 31, 2026
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in ChinaShun Lu, Baogang Liu, Yongzhong Luo, et al.
Lancet (London, England)|October 22, 2025
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trialZhiwei Chen, Fang Yang, Zhou Jiang, et al.
JAMA Surgery|July 15, 2026
Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non-Small Cell Lung Cancer: Post Hoc Analysis of the Neotorch Randomized Clinical TrialWentao Fang, Yiyang Wang, Wenxiang Wang, et al.
Thoracic Cancer|November 14, 2023
Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancerDingzhi Huang, Gen Lin, Qian Chu, et al.
Thoracic Cancer|January 14, 2024
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancerGen Lin, Zhijie Wang, Qian Chu, et al.
Pageof 10